A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma

References

• Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981–987.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• Spry NA, Lamb DS, Vaughan Hudson G, et al. Localized grade I non-Hodgkin's lymphoma: results of treatment with radiotherapy alone in 88 patients. Clin Oncol. 1989;1(1):33–38.
   Google Scholar
• Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64(3):928–934.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–3806.
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Newland AC, Hudson GV, et al. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol. 1994;11(1):19–25.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116(16):3843–3851.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30(27):3368–3375.
   PubMed Web of Science ®Google Scholar
• Vargo JA, Gill BS, Balasubramani GK, et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121(18):3325–3334.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–1423.
   PubMed Web of Science ®Google Scholar
• MacManus M, Fisher R, Roos D, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29):2918–2925.
   PubMed Web of Science ®Google Scholar
• Yang JC, Yahalom J. Early-stage follicular lymphoma: what is the preferred treatment strategy? J Clin Oncol. 2018;36(29):2904–2906.
   PubMed Web of Science ®Google Scholar
• Tobin JWD, Rule G, Colvin K, et al. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Adv. 2019;3(19):2804–2811.
   PubMed Web of Science ®Google Scholar
• Lo A, Campbell BA, Pickles T, et al. Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood. 2020;136(8):1006–1010.
   PubMed Web of Science ®Google Scholar
• Papaioannou D, Rafia R, Rathbone J, et al. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technol Assess. 2012;16(37):1–253.
   PubMed Web of Science ®Google Scholar
• Prettyjohns M, Hoskin P, McNamara C, NICE non-Hodgkin Lymphoma Clinical Guideline Committee, et al. The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. Br J Haematol. 2018;180(1):52–59.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol. 2008;19(3):570–576.
   PubMed Web of Science ®Google Scholar
• Australian Government Department of Health. Australian pharmaceutical benefits scheme; 2019 [cited 2020 Jun 11]. Available from: http://www.pbs.gov.au/pbs/home.
   Google Scholar
• Australian Government Department of Health. MBS online: medical benefits scheme; 2019 [cited 2020 Jun 11]. Available from: http://www.mbsonline.gov.au.
   Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.
   PubMed Web of Science ®Google Scholar
• Independent Hospital Pricing Authority. National efficient price determination 2018–19, Appendix H – price weights for admitted acute patients – AR-DRG V9.0, Independent Hospital Pricing Authority; 2018. Available from: https://www.ihpa.gov.au/publications/national-efficient-price-determination-2018-19. Accessed 11 June 2020.
   Google Scholar
• Australian Government Department of Health. Ibrutinib public summary document (PSD) March 2018 PBAC meeting pharmaceutical benefits scheme 2018 [cited 2020 Jun 11]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-03/Ibrutinib-psd-march-2018.
   Google Scholar
• Australian Government Department of Health. Brentuximab Vedotin public summary document (PSD) November 2018 PBAC meeting pharmaceutical benefits scheme; 2018 [cited 2020 Jun 11]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-11/Brentuximab-Vedotin-psd-november-2018.
   Google Scholar
• Australian Government Department of Health. Blinatumomab public summary document (PSD) July 2018 PBAC meeting pharmaceutical benefits scheme 2018 [cited 2020 Jun 11]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-07/Blinatumomab-psd-july-2018.
   Google Scholar
• Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51(5):1219–1227.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–463.
   PubMed Web of Science ®Google Scholar
• Barzenje DA, Cvancarova Smastuen M, Liestol K, et al. Radiotherapy compared to other strategies in the treatment of stage I/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLOS One. 2015;10(7):e0131158.
   PubMed Web of Science ®Google Scholar
• Brady JL, Binkley MS, Hajj C, et al. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237–245.
   PubMed Web of Science ®Google Scholar
• Gulácsi L, Brodszky V, Baji P, et al. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017;34(5):1128–1144.
   PubMed Web of Science ®Google Scholar
• Gregory GP, Carrington C, Cheah CY, et al. A consensus statement on the use of biosimilar medicines in hematology in Australia. Asia Pac J Clin Oncol. 2020;16(4):211–221.
   PubMed Web of Science ®Google Scholar
• Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295–3301.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. Version 4; 2018 [cited 2020 Jun 11] Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• Soini E, Martikainen J, Nousiainen T. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–1197.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Clinical Trials.gov. Radiation therapy and rituximab in treating patients with stage I-II grade 1 or grade 2 follicular lymphoma; 2020 [cited 2020 Jun 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01473628.
   Google Scholar
• Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma. 2008;49(2):227–236.
   PubMed Web of Science ®Google Scholar